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Context: The hypothalamic pituitary-adrenal (HPA) axis is thought to play a role in Type 2Diabetes
(T2D). However, the evidence for an association between diurnal cortisol patterns and T2D is
equivocal.
Objective: Theaimwas toexamine theassociationof cortisol patterns throughout thedaywithT2D
status in a community-dwelling population.
Design: Thiswas a cross-sectional studyof T2D status and salivary cortisol fromphase 7 (2002–2004)
of the Whitehall II study, United Kingdom.
Setting: The occupational cohort was originally recruited in 1985–1988.
Participants: 3508 white men and women including 238 participants with T2D aged 50–74 years
with complete information on cortisol secretion.
Outcome Measures: We measured diurnal cortisol (nmol/l) patterns from six saliva samples ob-
tained over the course of a normal day: atwaking,30min,2.5 h,8 h,12 h, and bedtime. The
cortisol awakening response and slope in diurnal secretion were calculated.
Results: T2D status was associated with a flatter slope in cortisol decline across the day (B 0.004,
C.I.  0.001 to 0.007, p  0.014) and greater bedtime cortisol (B  0.063, C.I.  0.010 to 0.117, p
0.020) independent of a wide range of covariates measured at the time of cortisol assessment.
Therewas no association betweenmorning cortisol, the cortisol awakening response and T2D (p
0.05).
Conclusions: In this non-clinical population, T2Dwas associatedwith a flatter slope in cortisol levels
across the day and raised bedtime cortisol values.
Type 2 diabetes (T2D) is a chronic metabolic and en-docrine disorder characterized by impaired insulin
resistance and pancreatic -cell dysfunction (1). The hy-
pothalamic pituitary adrenal (HPA) axis is thought to play
a role in T2D (2). Pathological (3) and experimental (4)
exposure to excessive cortisol (a product of the HPA sys-
tem) is related to metabolic disturbances such as hyper-
tension, hyperlipidemia and central obesity, all of which
are risk factors for T2D. Elevated cortisol concentrations,
assessed from single plasma samples (5) and 24 hour uri-
nary free samples (6) have been associated with raised
plasma glucose (5) and insulin resistance (5, 6) in healthy
participants. T2D is also a recognized complication of
long-term cortisol excess as seen in Cushing’s syndrome
(7) and in glucocorticoid-treated patients (8).
Increasingly, the marked diurnal patterning in the re-
lease of cortisol has been the focus of large-scale HPA axis
research (9). The diurnal cortisol pattern is typically char-
acterized by high cortisol levels on waking, followed by a
rise that reaches a peak 30 minutes after waking (termed
the cortisol awakening response (CAR)) and subsequent
decline across day (9). Flatter slope in cortisol over the day
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has been associated with diabetes-related outcomes such
as central adiposity (10) and an increased risk of cardio-
vascular disease (11). However, the reported associations
between diurnal cortisol patterns and T2D are equivocal.
In the Multi-Ethnic Study of Atherosclerosis (MESA)
cohort, participants with T2D were found to have a sig-
nificantly lowerCARthan thosewithoutT2D(12).Bruehl
et al (13), similarlyobservedabluntedCARinparticipants
with T2D, but found no association of T2D with slope in
cortisol across the day. In contrast, Lederbogen et al (14),
observed a flattened slope in diurnal cortisol secretion
among those with diabetes. Whereas, Vreeburg et al (15),
observed no association between diabetes status and the
CAR or diurnal cortisol slope.
The reasons for these divergent findings are unknown.
It is possible that differences in participant characteristics
or in the number and timing of cortisol samples between
studies may be involved. We therefore sought to examine
the association of diurnal cortisol secretion with diabetes
status in sample of 3508 community-dwelling men and
women of the Whitehall II study. We predicted that indi-
viduals with T2D would have a greater CAR and flatter
slope in cortisol across the day.
Methods and Measures
Participants
We used data from phase 7 (2002–2004) of the British
Whitehall II study. The cohort of 10,308 participants was
initially recruited between 1985 and 1988 from 20 Lon-
don-based civil service departments. The total number of
participants at phase 7 was 6967, and of these, 6484 had
a clinical assessment. Saliva collection for the assessment
of cortisol was instigated partway through phase 7 and of
those participants that were asked to collect saliva sam-
ples, 90.1% (n 4608) returned samples. This group had
fewer participants in the lowest civil service employment
grades compared with phase 1 of the study: however, this
difference was small. We restricted our analysis to those
with complete information on time of waking, cortisol
measures and diabetes status giving a final sample of 3508
participants (see Figure 1). Ethical approval for theWhite-
hall II study was obtained from the University College
LondonMedical School committee on the ethics of human
research. Informed consent for involvement in the study
was obtained from all participants.
Cortisol collection and analysis
The collection of cortisol from phase 7 of the study has
been described previously (16). Participants were pro-
videdwith a set of Salivettes and asked to take six samples
over the course of a normal weekday (Monday-Friday) at
waking, after 30 minutes, 2.5 hours, 8 hours, and 12
hours, and at bedtime. They were instructed not brush
teeth or consume any food or beverages for 15 minutes
prior to sample collection. An instruction booklet was
used to record information on the day of sampling includ-
ing wake time, time each sample was taken, and stressful
events. The salivettes and booklet were returned by post.
Salivettes were centrifuged at 3000g for 5 minutes result-
ing in a clear supernatant of lowviscosity. Salivary cortisol
levels were measured using a commercial chemilumines-
cence immunoassay (CLIA; IBL Hamburg, Germany).
The lower concentration limit of the assaywas 0.44 nmol/
liter and the intra- and interassay coefficients of variance
were less than 8%. Any sample over 50 nmol/ liter was
reanalyzed.
Figure 1. Flow diagram of participant included and excluded from the
analyses
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type 2 Diabetes
Type 2 diabetes was defined as a fasting glucose 7.0
mmol/l or a 2-hour post load glucose 11.1 mmol/l dur-
ing the oral glucose tolerance test (OGTT) performed at
the Whitehall clinical assessment or by reported doctor
diagnosed diabetes, or the use of diabetesmedication (17).
For the purposes of the OGTT, participants provided a
venous blood sample 8 hours after fasting and at 2 hours
post administration of a 75g glucose solution. Blood glu-
cose was measured using the glucose oxidase method (18)
on a YSI MODEL 2300 STAT PLUS Analyzer (YSI Cor-
poration, Yellow Springs, OH; mean coefficient of vari-
ation 1.4–3.1%) (19). Of the 238 participants with prev-
alent diabetes in our sample, 126 had known diabetes
(confirmed by report of doctor diagnosis and diabetic
medication) at the beginning of phase 7. A further 112
participants with diabetes were identified by the OGGT
carried out at the Whitehall clinical assessment.
Covariates
We used standard protocols to assess characteristics of
the participants at the time diurnal cortisol patterns were
measured (phase 7, 2002–2004). Age, sex, and current or
most recent civil service employment grade, a measure of
social position, were assessed by questionnaire. Smoking
status was defined as current smokers vs. noncurrent
smokers (16). Waking up time was assessed by partici-
pants’ records on the day of the collection of saliva. Time
difference between waking and taking first sample was
categorised into 5-minute intervals. Body mass index
(BMI) was assessed by measurement of height and weight
at the clinical assessment. Height was assessed using a
stadiometer with the head in the Frankfort plane, and
weight was assessed using a portable digital scale (Tanita,
Yiewsley, Middlesex, UK). BMI was calculated as weight
(in kilograms)/height (in meters) squared. For presenta-
tional purposes, BMI is categorised as obese (30 kg/m2)
or nonobese ( 29.9 kg/m2).We have previously reported
an association between fatigue and alterations in diurnal
cortisol secretion (20), and fatigue is common in individ-
uals with T2D (21). Therefore, we included fatigue as a
covariate in the study. Fatigue was assessed using the vi-
tality subscale of the Short Form-36(22). At the clinical
assessment it was recorded whether participants had a
history of coronary heart disease (CHD). Participants also
provided details of current medication use and these were
subsequently coded using the British National Formulary
(23). Cardiovascular medication usage was defined as the
use of-blockers, antihypertensives, lipid lowering drugs,
nitrates or antiplatelet medications.
Statistical analysis
Participants with cortisol values outside 3 SD from the
mean and those taking steroid medications were removed
from the analyses (n  171). Despite this, cortisol data
were skewed and were therefore logged for analysis. The
CAR was calculated by subtracting cortisol measured at
time 1 (waking) from cortisol measured at time 2 (30
minutes). Conventionally, analyses are restricted to sam-
ples that are collected within 10 minutes of waking (sam-
ple 1 taken 10 minutes, n 646) because of a reduced
CAR in those with longer delays (24). We did not see a
difference in sample delays by diabetes status so all par-
ticipants were retained. Most participants (n  3395,
96.8%) took cortisol sample 2 on time. We not see a dif-
ference in late sample 2 collection bydiabetes status so this
was not included as a covariate in the analyses. The
method used to calculate the diurnal slope in cortisol se-
cretionhasbeenpreviously described (10, 11, 20). In brief,
the slope of the decline in cortisol levels over the day was
calculated by regressing cortisol values on time after wak-
ing for samples 1 (waking), (2.5 hours), 4 (8 hours), 5
(12 hours), and 6 (bedtime). Because it is suggested that
theCARand slope in cortisol secretion are under different
neurobiological control systems (9), sample 2 was not in-
cluded to ensure that the CAR does not obscure the slope
calculation. Lower (more negative) slopes indicate a more
rapid decline in cortisol levels, whereas slope values closer
to zero reflect flatter diurnal rhythms. Descriptive and
clinical characteristics of the sample were compared using
t-tests for continuous variables and 2 tests for categorical
variables. Associations between prevalent diabetes and
the cortisol measures were analyzed using linear regres-
sion. Multivariable linear regressions using waking corti-
sol, CAR, slope and bedtime cortisol as outcome variables
were performed to analyze associations with prevalent di-
abetes. Age, sex, grade of employment, smoking, waking
time, late saliva collection, fatigue, BMI, cardiovascular
medication and history of CHD were included as covari-
ates in all analyses. Participants with missing covariate
information were excluded from the analyses. Previous
research has shown sex differences in the relationship be-
tween cortisol and diabetes status (12). Therefore, we in-
vestigatedwhether diabetes status interactedwith sex, but
found no significant associations with cortisol measures,
so interaction termswere not included in the final models.
We have previously shown a nonlinear relationship be-
tween BMI and slope (10). We investigated whether the
pattern of results changed including BMI as a quadratic
term. As the results were robust to controlling for the non-
linear effects of BMI, only BMI as a continuous variable
was included in the final models. Of the Whitehall II par-
ticipants who provided cortisol data 92.8% (n  3508)
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were of white ethnicity. We investigated whether preva-
lent diabetes interacted with ethnicity in the current sam-
ple. This interaction term was significant for slope (P 
.001) and bedtime cortisol (P .015). Therefore, we lim-
ited the present analysis to individuals of white ethnicity.
Results are presented as unstandardised regression coef-
ficients (B)with95%confidence intervals (C.I.). The slope
estimates were generated using 1 MLWin version 2.10
beta 6, all other analyses were conducted using SPSS ver-
sion 21 (SPSS, Chicago, IL, USA).
Results
We restricted our analysis to those with complete infor-
mation on time of waking, cortisol measures and diabetes
status. This resulted in 3508 participants. The character-
istics of participants included and excluded from the anal-
ysis are displayed in Table 1. The groups significantly dif-
fered in diabetic prevalence. However, this effect did not
remain when nonwhite participants were removed from
the excluded group (P .380, data not shown). The group
with complete cortisol data were younger, more likely to
be male and had fewer participants in the lowest civil ser-
vice employment grades. They were less likely to take car-
diovascular medication and have a history of CHD than
the phase 7 group who did not provide saliva samples.
The characteristics of the participants who provided
cortisol samples are displayed in Table 2. Two hundred
and thirty eight (6.78%) participants had prevalent dia-
betes at the time of saliva collection. The group with di-
abetes were older on average andweremore likely to be in
the lowest civil service employment grades. They were
more likely to be obese, have a history of CHD and take
cardiovascular medicine than those without diabetes.
Cortisol collection measures, such as waking time on day
of sampling did not differ by diabetes status.
The average CAR in the sample was 7.33 (SD 
11.575). As shown in Table 3 the CAR did not differ by
diabetes status (B  0.002, C.I.  –0.036 to 0.039, p
0.923). The average diurnal slope estimated from the hi-
erarchical linear model was –0.1290 nmol/l per h (SD 
0.023). Participants with diabetes had a flatter slope in
cortisol across the day than those without diabetes (B 
0.004, C.I. 0.001 to 0.007, P .014). This association
was robust to adjustment for age, sex, grade of employ-
ment, smoking, waking time, late saliva collection, fa-
tigue, BMI, cardiovascular medication and history of
CHD.A flatter slope in cortisol patterns across the day can
be due to low waking values or high evening values of
cortisol. We examined the association of these cortisol
measures with diabetes status.While participants with di-
abetes had higher waking levels on average compared to
those without diabetes, this difference was not signifi-
cantly different (B 0.014, C.I. –0.018 to 0.046, P
.383). In contrast, cortisol measures at bedtime differed
significantly between the groups. Participants with diabe-
tes had significantly greater bedtime cortisol values than
those without controlling for covariates (B  0.063, C.I.
 0.010 to 0.117, P  .020). This suggests that raised
evening cortisol levels accounted for thedifference in slope
between the two groups.
Discussion
This study investigated the cross-sectional association be-
tween components of the diurnal cortisol profile and di-
abetes status in a large population of community dwelling
adults. We found that the slope in cortisol across the day
was flatter in those with compared to those without T2D.
Our data suggest that the flat slope in cortisol in individ-
uals with T2D is due to raised late evening cortisol levels
rather than depressedmorning levels. These findings were
robust to adjustment for a range of covariates. No asso-
ciation emerged for the CAR.
Previous reports of the association between cortisol se-
cretion and diabetes status aremixed (12–15). In the pres-
Table 1. Characteristics of participants at phase 7 (2002–2004) of Whitehall II Study Means  standard deviations
and N (%)
Participants included in the
cortisol analyses (n  3508)
Participants excluded from the
cortisol analyses (n  3459) P value
Sex (% men) 2636 (75.1%) 2257 (65.3%) 0.001
Mean age (SD) 61.04 (5.94) 61.44 (6.06)  0.005
Current Smoker (% yes) 230 (6.6%) 274 (8.0%)  0.056
Employment grade (% lowest) 271 (7.7%) 489 (14.6%) 0.001
Mean BMI (SD) 26.68 (4.29) 26.84 (4.49)  0.131
Fatigued (% yes) 682 (19.5%) 700 (21.3%)  0.068
Cardiovascular medication (% yes) 1005 (28.6%) 1135 (33.1%) 0.001
History of CHD (% yes) 467 (13.7%) 570 (17.2%) 0.001
Type 2 Diabetes (% yes) 238 (6.78%) 309 (8.9%) 0.001
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ent study, we observed a flattened diurnal cortisol slope in
participants with T2D. This corroborates the results of
Lederbogen et al (14), who found an association between
diabetes status and flatter daily cortisol profiles in 979
individuals froma community cohort. Similar to our anal-
ysis, individuals with T2D were observed to have raised
evening cortisol concentrations compared to nondiabetic
controls. Elevated late-night cortisol levels have been sug-
gested as a diagnostic criterion for Cushing’s syndrome
(25).We removedparticipantswith veryhigh cortisol con-
centrations from our analysis, which would serve to ex-
clude individuals with Cushing’s syndrome. Our findings
were also independent of obesity, which is strongly asso-
ciated with the disorder. Indeed, raised late-night salivary
cortisol levels have been previously been described in in-
dividuals with diabetes but without Cushing’s syndrome
(26).
In contrast to our findings, Vreeburg et al, (15) found
no association between T2D and diurnal cortisol slope in
491 individuals without psychopathology from the Neth-
erlands Study of Depression and Anxiety (NESDA) co-
hort. Participants in the study provided four saliva sam-
ples within an hour of waking and two late-evening
samples. The additional samples collected in the late
morning and afternoon in the present investigation may
account for the diverging findings, as we were better able
to define the shape of the diurnal cortisol curve. It is pos-
sible that the lack of information on late morning and
afternoon cortisol levels reduced the ability of Vreeburg et
al to examine the curvilinear nature of the decline in cor-
tisol across the day (9).
We failed to find an association betweendiabetes status
and the CAR. This result is in contrast to the findings of
Bruehl et al (13) and Champaneri et al (12) and who ob-
served a blunted CAR in T2D individuals relative to con-
trols. The reasons for the inconsistent results are unclear.
However, our study is considerably larger than previous
studies and consisted of a well-defined group of white
community dwelling individuals. In contrast, the study by
Bruehl et al (13), was limited by low participant numbers
and a lack of adjustment for potential confounding fac-
tors. Champaneri et al (12), investigated the association
between diabetes status and cortisol secretion in a cohort
of over a 1000 individuals. However, the sample usedwas
ethnically diverse and over 60% of the participants were
of Hispanic origin. The present study was unpowered to
detect the potential ethnic differences in the association
between cortisol secretion and T2D and this may account
for the differing findings between the studies.
Waking cortisolwas not related todiabetes status in the
current analysis. We have previously reported a relation-
ship between fatigue and lower cortisol on waking (20)
and fatigue is a common complaint among individuals
with diabetes (21). Fatigue was independently associated
with the diurnal cortisol slope and bedtime cortisol in the
present study (data not shown). However, the association
between T2D and these cortisol measures was robust to
adjustment for this factor.
Table 2. Characteristics of participants at time of cortisol assessment by diabetes status Means  standard
deviations and N (%)
N of
participants
No diabetes
(n  3270)
Prevalent Diabetes
(n  238) P value
Mean age (SD) 3508 60.85 (5.89) 63.64 (5.99) 0.001
Sex (% men) 3508 2455 (75.1%) 181 (76.1%)  0.816
Current Smoker (% yes) 3506 212 (6.5%) 18 (7.6%)  0.522
Employment grade (% lowest) 3498 237 (7.3%) 34 (14.3%) 0.001
Obese (% yes) 3494 567 (17.4%) 80 (33.8%) 0.001
Fatigued (% yes) 3491 625 (19.2%) 57 (24.1%)  0.075
Late saliva collection (% yes) 3508 597 (18.3%) 49 (20.6%) 0.386
Cardiovascular medication (% yes) 3508 861 (26.3%) 144 (60.5%) 0.001
History of CHD (% yes) 3398 407 (12.8%) 60 (26.2%) 0.001
Table 3. Mean scores of measures of cortisol by diabetes status at phase 7 Means  standard deviations
Prevalent Diabetes
(n  238)
No diabetes
(n  3270)
P
value
Adjusted
P value
Waking cortisol (nmol/liter) 16.32 (7.74) 15.82 (7.18) 0.383
CAR (nmol/) 7.35 (10.64) 7.54 (10.96) 0.923
Slope across the day (nmol/liter per h) 0.125 (0.022) 0.129 (0.023) 0.002 0.014
Bedtime cortisol (nmol/) 2.59 (2.57) 2.34 (2.95) 0.002 0.020
*Adjusted for age, sex, smoking, grade of employment, waking time, fatigue, late saliva collection, BMI, CVD medication, and history of CHD.
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The causes of a flattened slope in diurnal cortisol are
unknown and the mechanisms by which T2D is related to
the HPA axis also remain to be elucidated. Cortisol plays
a pivotal role in many physiological processes relevant to
diabetes. It directly reduces insulin sensitivity and de-
creases insulin secretion by acting through glucocorticoid
receptors, which are expressed on pancreatic -cells. It
triggers hepatic gluconeogenesis, promotes lipolysis and
the release of fatty free acids into the circulation and the
accumulationof triglycerides in adipose tissue (2).Obesity
is common in T2D and visceral adipose tissue expresses
high levels of glucocorticoid receptors (27). It has been
hypothesized that adipocytes are a source of cortisol. Re-
search has shown that transgenic mice overexpressing
11-hydroxysteroid dehydrogenase type 1 (11-HSD1),
the enzymeactivating the inactive formof glucocorticoids,
have increased adipose levels of corticosterone (28). In-
creased 11-HSD1 activity in human visceral adipose tis-
sue has been associated with symptoms of the metabolic
syndrome (29). Thus, obesity offers one possible mecha-
nism through which T2D might be associated with alter-
ations in cortisol secretion.
Participants with diabetes in our sample were signifi-
cantly more likely to be obese and obesity has been asso-
ciated with a flattened slope in diurnal cortisol secretion
(10). As previously reported (10), BMI as a continuous
measure was not associated with the slope in diurnal cor-
tisol secretion. However, obesity was independently as-
sociated with the diurnal cortisol slope and bedtime cor-
tisol (data not shown). Despite this the relationship
between diabetes status and these cortisol measures was
robust to adjustment for obesity.
Inflammation is another pathway through which T2D
might be related to alterations in HPA axis function. In-
flammatory cytokines are involved in the pathogenesis of
T2D. Circulating cytokine levels are elevated in diabetic
individuals (30) and heightened concentrations are pre-
dictive of T2D development in initially healthy samples
(31).Cortisol is involved in the regulationof inflammation
(2) and circadian rhythms are regulated at the hypotha-
lamic level by the suprachiasmatic nuclei. It has been sug-
gested that circadian control is an important aspect of
hypothalamic-immune communication, and that gluco-
corticoids may dysregulate the immune response via cir-
cadian-immune communication (32). It is also possible
that disturbances in circadian rhythms may act on T2D
through the alteration of glucose metabolism. Recent ex-
perimental work indicates that circadian disruption in-
creases both fasting and postprandial plasma glucose con-
centrations through inadequate pancreatic insulin
secretion (33). Additional research is needed to examine
whether changes in inflammation and alterations in glu-
cose metabolism may underlie the association between
flatter slopes in diurnal cortisol section and T2D.
Another mechanism that may explain the relationship
between diurnal cortisol slope and T2D is psychosocial
stress. Results from meta-analyses and longitudinal stud-
ies indicate that psychosocial factors increase the risk of
developing T2D (34) and contribute to disease progres-
sion in diabetic individuals (35). Cortisol levels are ele-
vated by exposure to stress (36) and the flattening of the
diurnal cortisol slope has been associated with both acute
and chronic stress factors (37). Acute stress assessed by
stressful events on the day of saliva sampling was not as-
sociatedwith the slope in cortisol or evening cortisol in the
current analysis andour findings remained independent of
acute stress (data not shown). However, it is possible that
the findings could be attributed to long-term changes in
circadian regulation as a result of chronic stress in people
with T2D. Additional research is needed to examine
whether chronic stress factors may underlie the associa-
tion of flattened diurnal cortisol slopes with T2D.
In the present study we assessed cortisol across the day
in a large community-based sample. The participantswith
T2Dwerewell-characterized andwewere able to use data
from the larger cohort study to adjust for a number of
potentially confounding factors in our analysis. However,
our findings should be interpreted in light of some limi-
tations. The Whitehall II study is an occupational cohort
of civil servants and as such, our sample is not represen-
tative of the general population. The larger cohort study is
predominately of white ethnicity, and due to ethnic dif-
ferences in the pathogenesis of T2D we restricted the cur-
rent analysis to white individuals. Therefore, the present
results may not generalize to other populations. T2D was
assessed by self-report of doctor diagnosis, use of diabetic
medications or OGGT rather than clinical diagnosis. We
also lacked data on the duration of T2D, which may be
related to neuroendocrine function. The associations ob-
served in the analyseswere small.However, these patterns
are thought to be representative of chronic differences that
are present on an everyday basis. Under these circum-
stances, evenmodest effects may contribute to substantial
accumulateddifferences in cortisol outputover time. Stud-
ies specifically designed to test the association between
T2D and neuroendocrine function would provide richer
data. The cross-sectional design makes it impossible to
draw causal conclusions about the temporal relationship
between aberrant cortisol output and diabetes. Cortisol
was assessed over a single day and it has been suggested
that this may obscure the CAR to situational rather than
chronic correlates (38). Furthermore, the night release of
cortisol was not assessed and therefore it was not possible
to evaluate total 24 hour circadian cortisol exposure. We
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only measured free cortisol levels in the study and did not
assess glucocorticoid receptor function. It is possible that
the findings reflect reduced episodic cortisol releasewhich
has been reported to modify the regulation of glucocorti-
coid sensitive genes (39). We relied on self-report for the
timing of sample collection. Our prevalence of ‘late’ re-
porting was similar to previously reported rates (24) and
evidence suggests that participants are generally accurate
in their recording of this information (40) .
Despite these considerations, our findings indicate that
flat slopes in salivary cortisol, particularly raised evening
levels of cortisol are associated with T2D in nonclinical
population of middle-aged men and women. The mecha-
nisms by which these associations occur remain to be de-
termined. It is possible that neuroendocrine dysfunction
may be related to the pathophysiology of T2D. However,
longitudinal studies are required to assess the prognostic
properties of cortisol secretion for T2D.
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